KLOW Blend (BPC-157 + TB-500 + GHK-Cu + KPV)

What Is the KLOW Blend?

The KLOW blend is a four-peptide research formulation that combines BPC-157, TB-500, GHK-Cu and KPV in a single vial. “KLOW” is a supplier name, not a scientific term, and the formulation is a supplier-defined combination, not an approved or standardized product.

Suppliers commonly list it as 80 mg total per vial, without a standardized split among the four components, so the label and batch certificate of analysis are the only guide to how much of each peptide a vial contains.

The components come from separate lines of research. BPC-157 is a synthetic pentadecapeptide originally isolated from gastric juice and studied across many animal models of tissue repair.^[1] TB-500 is a name usually associated with thymosin beta-4 (Tβ4), a naturally occurring 43-residue peptide, although a 2026 review in Sports Medicine lists the two separately and describes TB-500 as a thymosin beta-4 fragment.^[2] GHK-Cu is the copper(II) complex of the tripeptide GHK, which is present in human plasma, saliva and urine and declines with age.^[3] KPV is the tripeptide Lys-Pro-Val, which corresponds to residues 11 to 13 of alpha-melanocyte-stimulating hormone (alpha-MSH).^[4]

Components at a Glance

The blend combines two larger peptides with two tripeptides, and each has a different primary mechanism in the published literature. Molecular weights are from PubChem.

Full-length thymosin beta-4 is more than 14 times the mass of KPV. A thymosin beta-4 fragment would weigh much less, so mass spectrometry data confirm which form is present.

Why These Compounds Are Studied Together

The four peptides are grouped because each has been studied in tissue-repair or inflammation research, not because a defined interaction among them has been demonstrated. No study in the component literature has tested the four-peptide combination, so the evidence comes from separate studies of each component.

Overlapping tissue-repair research

A 2026 orthopedic review groups BPC-157, TB-500 and GHK-Cu as wound-healing peptides that promote angiogenesis, integrin-mediated extracellular matrix remodeling and fibroblast activation.^[7] In preclinical models, BPC-157 improved functional, structural and biomechanical outcomes in muscle, tendon, ligament and bone injuries.^[8] Thymosin beta-4 increased blood vessel growth in small and large animal models and showed antifibrotic effects in vitro and in animal models.^[9]

Where KPV fits

KPV is the component least connected to the others in the published record. Its research centers on intestinal inflammation: in human intestinal epithelial cells and T cells, nanomolar concentrations of KPV reduced NF-κB and MAP kinase activation, with uptake dependent on PepT1.^[6] In mouse DSS and transfer colitis models, KPV reduced inflammatory infiltrates and myeloperoxidase activity.^[10] A 2025 review of tripeptides in wound healing discusses KPV-loaded hydrogels, which reduced inflammation, promoted tissue regeneration and combated MRSA infections, alongside GHK-based formulations.^[11]

GHK-Cu has anti-inflammatory data of its own. In mice exposed to cigarette smoke, it lowered IL-1β and TNF-α and reversed the smoke-induced rise in NF-κB expression in lung tissue.^[12] These parallel findings explain why the peptides are discussed together; they do not show that combining them changes any component’s effect.

Direct combination data

The only combination data in the component sources involve two of the four peptides. In a retrospective knee pain chart review at a single clinic, 4 of the 16 patients reached by phone had received both BPC-157 and thymosin beta-4, and 3 of those 4 reported significant improvement.^[13] The review had no control group and used no standardized outcome measures. No study pairing GHK-Cu or KPV with the other components was found, and claims of synergy are not supported by published data.

With four peptides in one vial and no standard split, researchers check that HPLC and mass spectrometry data confirm each component and its stated amount.

Research Status

The KLOW blend is not an approved product, and none of its four components is FDA approved as a drug. It is sold as a research material only.

The evidence behind each component is mostly preclinical. A 2025 systematic review of BPC-157 in orthopedic sports medicine included 36 studies, 35 of them preclinical, and rated the evidence as level IV and V.^[8] Only three small human pilot studies of BPC-157 have been described.^[1] Clinical work on thymosin beta-4 has focused on eye drops, which reached phase 3 trials for dry eye and neurotrophic keratopathy.^[14] GHK-Cu is widely used in cosmetics under the INCI name copper tripeptide-1, yet reviewers note a surprising absence of clinical studies even for its topical use.^[15] KPV data come from cell culture and rodent colitis models.^[6][10]

A 2026 Sports Medicine review places BPC-157, GHK-Cu, thymosin beta-4 and TB-500 among peptides marketed directly to patients through a gray market largely outside regulatory oversight, and notes that rigorous human safety data are scarce, with potential for serious harm.^[2] A 2026 orthopedic primer adds that thymosin beta-4 and TB-500 remain banned substances in sports and that the indications and treatment parameters for these peptides are unknown.^[16]